Sunshine Biopharma Amends Articles Of Incorporation To Allow For Reverse Stock Split Of Up To 1-For-20; Board Of Directors Has Discretion To Effect The Split
On September 15, 2026, the Company received written consent in lieu of a meeting of stockholders from Dr. Steve N. Slilaty, our Chief Executive Officer, the holder of approximately 97% of the total voting power of the
Sunshine Biopharma got permission to do a reverse stock split. This happens when a company wants to change how many shares exist, which often means the stock price was very low.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.